Eosinophilic esophagitis (EoE) shows characteristic microscopic pathologic features in endoscopically obtained esophageal biopsies, including an eosinophil-rich inflammatory infiltrate in esophageal epithelium, but other inflammatory cells are also increased. Additional alterations…
Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis (EoE) are not mutually exclusive. The notion that GERD and EoE can be distinguished by the response to proton pump inhibitor (PPI) treatment…
Initial case series describing children and adults with symptoms related to esophageal dysfunction and dense esophageal eosinophilia lead to recognition of a “new” disease, eosinophilic esophagitis (EoE). Clinical, basic, and…
Eosinophilic esophagitis (EoE) is increasing in western nations. Symptoms in infants and young children include feeding difficulties, failure to thrive, and gastroesophageal reflux. School-aged children may present with vomiting, abdominal…
Eosinophilic esophagitis (EoE) is an increasingly recognized immune antigen-mediated esophageal disease found in both children and adults. It is defined as a clinicopathologic disease characterized by symptoms of esophageal dysfunction…
In this article, the epidemiology of eosinophilic esophagitis (EoE) is reviewed. Demographic features and natural history are described, the prevalence and incidence of EoE are highlighted, and risk factors for…
Ikuo Hirano, MD, Editor Eosinophilic esophagitis (EoE) has emerged over the past two decades as an important cause of upper gastrointestinal symptoms in both adults and children. Defined as a…
Gary W. Falk, MD, MS, Editor Eosinophilic esophagitis (EoE) is a disease that was virtually unheard of 20 years ago. Yet, in recent years, there has been an explosive increase…
Biologic therapies, including the anti–tumor necrosis factor-α and cell adhesion molecule inhibitor drugs, have revolutionized the treatment of moderate-to-severe inflammatory bowel disease. Since the introduction of anti–tumor necrosis factor therapies,…
Despite the success of antitumor necrosis factor (TNF) therapy in Crohn’s disease, there remains a need for biologic therapy that targets other immune pathways of disease. Ustekinumab is a fully…
